tb-500 mastery course
Unit 7 of 12

cardiac & neurological research

from Bock-Marquette's Nature 2004 cardiac repair study to neurological protection and progenitor cell activation

Heart and Brain

Bock-Marquette (Nature, 2004) showed TB4 activated cardiac progenitor cells and improved heart function after MI in mice by engaging the ILK/Akt survival pathway -- reducing infarct size by roughly 50% and seeding the RegeneRx clinical program that followed in preclinical development.

Parallel animal work flags neuroprotective signals in TBI, stroke, and MS models. This unit walks why pharma money never produced an approved drug.

~50%
infarct-size reduction in mice (Bock-Marquette 2004)
2001
RegeneRx licenses TB4
Phase 2
where the cardiac program stalled
RGN-259
only surviving clinical path (ophthalmic)

Map the Organ Findings

Click a system to pull its animal studies.

organ research map

Nature 2004: the study that seeded RegeneRx

TB4-treated mice vs saline controls across the four post-MI metrics Bock-Marquette measured -- and why dose timing mattered nearly as much as dose.

tb4 vs control -- post-MI cardiac metrics

cardiac & neurological research -- the simple version

what the heart and brain studies actually showed, explained without the jargon.

In 2004, researchers gave TB-500 to mice after heart attacks and found it cut the damaged area roughly in half. It did this by activating a survival switch called Akt (a protein inside cells that tells them to stay alive instead of self-destructing). TB-500 also helped grow new blood vessels into the damaged heart tissue and reduced scarring. Separately, rodent studies showed TB-500 protected brain cells after stroke and traumatic brain injury. In a multiple-sclerosis-like model, it helped repair the protective coating around nerve fibers. The catch: all of this is animal data. Only one tiny human study (10 patients) has been done, and it used TB-500 to prep stem cells, not as a direct injection. Whether subcutaneous TB-500 actually reaches the brain through the blood-brain barrier (the protective filter that blocks most molecules from entering brain tissue) is unknown.

A advanced: Bock-Marquette 2004 and the ILK/Akt cardioprotection mechanism term
The Nature 2004 paper showed Tb4 activates integrin-linked kinase (ILK) in cardiomyocytes, which phosphorylates Akt at Ser473. Activated Akt inhibits the pro-apoptotic protein Bad and activates anti-apoptotic Bcl-xL, reducing cardiomyocyte death in the peri-infarct zone. The mechanism is anti-apoptotic (preventing cell death), not regenerative (creating new cells). The therapeutic window was narrow: Tb4 had to be given within 24 hours of coronary ligation. Neovascularization via VEGF upregulation provided additional benefit by improving blood supply to surviving myocardium.
advanced: epicardial progenitor reactivation (Smart 2007 vs Zhou 2012)
Smart et al. (2007) showed Tb4 reactivated dormant WT1+/Tbx18+ epicardial progenitor cells, inducing epithelial-to-mesenchymal transition and migration into injured myocardium. These cells differentiated into smooth muscle cells and fibroblasts for vascular support. The contested claim was cardiomyocyte generation. Zhou et al. (2012), using improved lineage-tracing tools, found Tb4 after MI did not reprogram epicardial cells into functional cardiomyocytes. The field now accepts that Tb4 provides vascular improvement and tissue preservation, not true cardiac muscle regeneration.
advanced: neuroprotection, the BBB problem, and miR-200a
In rodent stroke models, systemic Tb4 reduced infarct volume by 20-35% and enhanced neuroblast migration from the subventricular zone to peri-infarct cortex. In EAE (MS model), Tb4 promoted oligodendrocyte progenitor migration and remyelination. At the molecular level, Tb4 upregulates miR-200a, a microRNA that drives neural progenitor differentiation. However, TB-500 at 4,921 Da is nearly ten times the 500 Da passive BBB permeability cutoff. It likely reached brain tissue only through injury-disrupted barriers. No study has measured CSF or brain concentrations after systemic administration.

cardiac vs neurological evidence -- two different gaps

the cardiac program reached human trials; the neurological arm never did.

cardiac evidence

  • best study: Bock-Marquette et al., Nature 2004 (mouse MI model)
  • mechanism: ILK/Akt anti-apoptotic; epicardial progenitor reactivation
  • clinical progress: one small 10-patient Phase I stem-cell priming study
  • why stalled: the Smart vs Zhou controversy on cardiomyocyte regeneration undermined investor confidence
  • verdict: compelling animal data; regulatory path blocked by unresolved mechanism disputes

neurological evidence

  • best study: Xiong et al. 2012 (rat TBI model); Morris 2014 (EAE MS model)
  • mechanism: neuroblast migration, oligodendrocyte differentiation, miR-200a upregulation
  • clinical progress: zero -- no IND filed for neurological indication
  • why stalled: BBB penetration unconfirmed (TB4 is ~10x the passive-permeability cutoff)
  • verdict: interesting rodent signal; delivery problem unsolved for human translation

key terms

cardiac biology — ILK (integrin-linked kinase)

serine/threonine kinase at the integrin-cytoskeleton junction that TB4 activates to promote cardiomyocyte survival and migration into damaged myocardium.

cardiac biology — epicardial progenitor cells

cells lining the outer surface of the heart that, when activated by TB4, can re-enter the myocardium and differentiate into cardiomyocytes and vascular cells.

neuroprotection — blood-brain barrier

the selective barrier between blood and brain tissue. whether subcutaneous TB-500 crosses it in clinically meaningful amounts is unresolved and limits translation of rodent TBI data.

neuroprotection — demyelination

loss of the myelin sheath around nerve fibers, as seen in MS. TB4 promoted remyelination in EAE (experimental autoimmune encephalomyelitis) mouse models but has not been tested in human MS.